Pharmabiz
 

Biocon Q2FY27 revenues at Rs. 4,389 crore up by 2%, net profit dips by 51% at Rs. 41 crore

Our Bureau, Bengaluru, Wednesday, November 4, 2026, 17:25 Hrs  [IST]

Biocon in its consolidated financial results for the fiscal second quarter ended September 30, 2026 registered operating revenue of Rs. 4,389 crore. This was 2% rise YoY.  Consolidated EBITDA stood at Rs. 865 crore. Net profit dips 51 reporting Rs. 41 crore.
 
The Bengaluru-based company’s biopharma revenue increased 5% YoY to Rs. 3,583 crore, biosimilars revenue increased 3% YoY to Rs. 2,809 crore and generics revenue increased 10% YoY Rs. 774 crore, Services revenue increased 13% QoQ to Rs. 833 crore.
 
“Biocon continued to achieve industry firsts in biosimilars, with our pertuzumab becoming the first monoclonal antibody biosimilar recommended under the EMA’s new tailored clinical development pathway. This represents an important milestone for biosimilar innovation and patient access. The operationalization of our second insulin glargine fill-finish line in Malaysia, with commercial supplies already underway, further reaffirms our global manufacturing excellence. Together with our continued investments in technology and innovation, these milestones reflect the progress of our strategic transformation and reinforce our confidence in Biocon’s long-term growth trajectory,” said Kiran Mazumdar-Shaw, executive chairperson, Biocon.
 
“This quarter we continued to make significant progress on our strategic priorities, laying the foundation for a stronger second half of FY27. Our global settlement with Genentech for Pebrilzo (biosimilar Pertuzumab) secured the earliest licensed launch dates across Europe, UK, the U.S. and emerging markets providing greater visibility to a significant future growth driver. We also secured a landmark 10-year Pertuzumab PDP partnership in Brazil valued at ~USD 400 million, underscoring our ability to win and execute large-scale biologics deals. Together with the upcoming European launch of Pertuzumab, expanded insulin manufacturing capacity in Malaysia to support growing US demand, and the strong early momentum of Yesafili and Yesintek in the US, we are well positioned for growth in the second half of FY27,” stated Shreehas Tambe, CEO & managing director, Biocon.
 
“Syngene delivered 13% sequential revenue growth in Q2, supported by positive traction in our CDMO business, with operating EBITDA margin improving by 6 percentage points. Year-on-year revenue declined 9%, while operating EBITDA margin stood at 18%, in line with expectations, primarily reflecting lower Zoetis revenues and forex hedge losses. A key milestone in the quarter was the signing of our first manufacturing agreement for the Bayview biologics facility in the US. Our focus remains on improving our integrated drug discovery offering, commercial execution, asset utilization and cost competitiveness to drive sustainable growth,” said Siddharth Mittal, CEO & managing director, Syngene International.  

 
[Close]